International Stem Cell Corporation

OTCPK:ISCO Stock Report

Market Cap: US$960.5k

International Stem Cell Past Earnings Performance

Past criteria checks 0/6

International Stem Cell has been growing earnings at an average annual rate of 56%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 1.2% per year.

Key information

56.0%

Earnings growth rate

56.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-1.2%
Return on equity-261.8%
Net Margin-6.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How International Stem Cell makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ISCO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249-150
30 Jun 248050
31 Mar 248050
31 Dec 238050
30 Sep 238050
30 Jun 238050
31 Mar 238050
31 Dec 228050
30 Sep 228-150
30 Jun 228-150
31 Mar 228060
31 Dec 217-160
30 Sep 217-160
30 Jun 216-260
31 Mar 216-360
31 Dec 207-370
30 Sep 208-580
30 Jun 209-480
31 Mar 2010-490
31 Dec 199-491
30 Sep 199-391
30 Jun 1910-291
31 Mar 1911-282
31 Dec 1811-282
30 Sep 1811-272
30 Jun 189-572
31 Mar 188-472
31 Dec 177-672
30 Sep 177-372
30 Jun 177072
31 Mar 1781073
31 Dec 167-173
30 Sep 167-572
30 Jun 168-672
31 Mar 168-1672
31 Dec 158-372
30 Sep 157-674
30 Jun 157-785
31 Mar 157-1286
31 Dec 147-1285
30 Sep 147-1194
30 Jun 147-1294
31 Mar 147-1093
31 Dec 136-1093

Quality Earnings: ISCO is currently unprofitable.

Growing Profit Margin: ISCO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ISCO is unprofitable, but has reduced losses over the past 5 years at a rate of 56% per year.

Accelerating Growth: Unable to compare ISCO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ISCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: ISCO has a negative Return on Equity (-261.78%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies